Bio-Rad Laboratories (BIO) Net Cash Flow (2009 - 2026)

Bio-Rad Laboratories (BIO) has 18 years of Net Cash Flow data on file, last reported at -$29.1 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 182.91% year-over-year to -$29.1 million in Q1 2026; TTM through Mar 2026 was -$4.9 million, a 105.79% decrease from a year earlier, with the FY2025 full-year figure at $59.3 million, down 22.18% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$29.1 million, down from $134.0 million in the prior quarter.
• Over the last five years, Net Cash Flow for BIO reached as high as $324.6 million in Q1 2022 and fell as low as -$212.5 million in Q2 2022.
• Historically, Net Cash Flow has averaged $2.1 million across 5 years, with a median of $11.9 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 1711.03% in 2022 and fell as far as 471.36% in 2022.
• Year by year, Net Cash Flow stood at -$65.5 million in 2022, then climbed by 27.71% to -$47.4 million in 2023, then surged by 242.47% to $67.5 million in 2024, then jumped by 98.52% to $134.0 million in 2025, then tumbled by 121.72% to -$29.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$29.1 million in Q1 2026, $134.0 million in Q4 2025, and $25.4 million in Q3 2025.